At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NRSN Neurosense Therapeutics Ltd
Pre-Market Trading 06-13 05:37:43 EDT
1.03
+0.02
+1.98%
High1.13Low1.00Vol127.42K
Open1.00D1 Closing1.01Amplitude12.86%
Mkt Cap18.58MTradable Cap12.75MTotal Shares18.04M
T/O137.56KT/O Rate1.03%Tradable Shares12.38M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
NeuroSense Therapeutics Sets Date for AGM
TIPRANKS  ·  05-24
NeuroSense Therapeutics Sets Date for AGM
NeuroSense Reveals Promising ALS Therapy Progress
TIPRANKS  ·  05-20
NeuroSense Reveals Promising ALS Therapy Progress
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit
PR Newswire  ·  05-20
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit
NeuroSense Optimizes ALS Trial with Machine Learning
TIPRANKS  ·  05-14
NeuroSense Optimizes ALS Trial with Machine Learning
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
PR Newswire  ·  05-14
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
NeuroSense’s PrimeC Shows Promise in ALS Trial
TIPRANKS  ·  05-07
NeuroSense’s PrimeC Shows Promise in ALS Trial
BRIEF-NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
Reuters  ·  05-07
BRIEF-NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
PR Newswire  ·  05-07
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
NeuroSense Announces First Quarter 2024 Business Update
PR Newswire  ·  05-02
NeuroSense Announces First Quarter 2024 Business Update
BRIEF-Neurosense And Genetika+ Initiate Precision Medicine Collaboration
Reuters  ·  04-22
BRIEF-Neurosense And Genetika+ Initiate Precision Medicine Collaboration
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
PR Newswire  ·  04-22
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
PR Newswire  ·  04-18
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
NeuroSense Launches Pre-Funded Warrants Offering
TIPRANKS  ·  04-13
NeuroSense Launches Pre-Funded Warrants Offering
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
PR Newswire  ·  04-12
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
NeuroSense Therapeutics sheds 6%, on $4.5M direct private offering
seekingalpha  ·  04-11
NeuroSense Therapeutics sheds 6%, on $4.5M direct private offering
NeuroSense Advances ALS Therapy with Promising Trials
TIPRANKS  ·  04-11
NeuroSense Advances ALS Therapy with Promising Trials
BRIEF-Neurosense Announces Pricing Of $4.5 Million Registered Direct Offering And Concurrent Private Placement
Reuters  ·  04-11
BRIEF-Neurosense Announces Pricing Of $4.5 Million Registered Direct Offering And Concurrent Private Placement
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
PR Newswire  ·  04-11
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
NeuroSense Partners with Lonza on ALS Biomarker Research
TIPRANKS  ·  04-09
NeuroSense Partners with Lonza on ALS Biomarker Research
BRIEF-Biotech Firm NeuroSense Collaborates With Lonza To Identify Exosome-based Biomarkers
Reuters  ·  04-09
BRIEF-Biotech Firm NeuroSense Collaborates With Lonza To Identify Exosome-based Biomarkers

Introduction

Company Name.
Neurosense Therapeutics Ltd
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Issue price:
--